|Chemical and physical data|
|Molar mass||348.49 g/mol g·mol−1|
|3D model (JSmol)|
CUMYL-PICA (SGT-56) is an indole-3-carboxamide based synthetic cannabinoid. It is the α,α-dimethylbenzyl analogue of SDB-006. It was briefly sold in New Zealand during 2013 as an ingredient of at the time legal synthetic cannabis products, but the product containing CUMYL-BICA and CUMYL-PICA was denied an interim licensing approval under the Psychoactive Substances regulatory scheme, due to reports of adverse events in consumers. CUMYL-PICA acts as an agonist for the cannabinoid receptors, with Ki values of 59.21 nM at CB1 and 136.38 nM at CB2 and EC50 values of 11.98 nM at CB1 and 16.2 nM at CB2.
- "CUMYL-PICA". Cayman Chemical. Retrieved 8 July 2015.
- "The Risk Assessment Score Table. New Zealand Ministry of Health, 27 September 2013" (PDF). Archived from the original (PDF) on 2014-01-08. Retrieved 2015-07-09.
- Gamage, Thomas F.; Farquhar, Charlotte E.; Lefever, Timothy W.; Marusich, Julie A.; Kevin, Richard C.; McGregor, Iain S.; Wiley, Jenny L.; Thomas, Brian F. (April 2018). "Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA". Journal of Pharmacology and Experimental Therapeutics. 365 (1): jpet.117.246983. doi:10.1124/jpet.117.246983. ISSN 0022-3565. PMC 5932312. PMID 29549157.
- Bowden; et al. (11 April 2013). "Patent WO 2014167530 - Cannabinoid compounds". New Zealand Patent application 623626. Retrieved 11 July 2015.